SCHEMBL1014948

SCHEMBL1014948

CSc1ncc(C(=O)O)c(C2CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 1/20 0.43
PDE4B Q07343 2/20 0.40
KDM6B O15054 1/20 0.40
KDM4A O75164 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
HIF1AN Q9NWT6 1/20 0.40
KDM2A Q9Y2K7 1/20 0.40
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
THRB P10828 1/20 0.38
AHR P35869 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
DHODH Q02127 1/20 0.37
NTRK1 P04629 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1587409 0.94 KMT2A (0.44) MEN1KMT2AKDM4EPDE4BKDM6B
SCHEMBL1014147 0.94 KMT2A (0.44) MEN1KMT2AKDM4EPDE4BKDM6B
SCHEMBL1014941 0.93 KMT2A (0.43) MEN1KMT2AKDM4EPDE4BKDM6B
SCHEMBL28305461 0.86 PIM1 (0.43) MEN1KMT2AKDM4EPDE4BAHR
SCHEMBL1015391 0.84 MEN1 (0.41) MEN1KMT2AKDM4EPDE4BKDM6B
SCHEMBL25308090 0.84 PDE4B (0.43) MEN1KMT2APDE4BALDH1A1POLB
SCHEMBL29483810 0.84 PDE4B (0.43) MEN1KMT2APDE4BALDH1A1POLB
SCHEMBL17092337 0.81 HPGD (0.50) MEN1KMT2AKDM4EALDH1A1POLB
SCHEMBL1015587 0.80 MEN1 (0.59) MEN1KMT2AKDM4EALDH1A1POLB
SCHEMBL1014376 0.79 MEN1 (0.40) MEN1KMT2AKDM4EPDE4BKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 MEN1 1994/4885KMT2A 1860/4885KDM4E 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.